Development of strategies for the use of anti-growth factor treatments

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Aberrant epidermal growth factor receptor (EGFR) signaling drives cancer progression.
• EGFR is a validated target for cancer therapy, with inhibitors like gefitinib showing efficacy.
• Resistance to EGFR inhibitors is a significant clinical challenge.

Purpose of the Study:

• To investigate the mechanisms of de novo and acquired resistance to gefitinib.
• To identify alternative therapeutic targets that can overcome gefitinib resistance.
• To evaluate combination strategies involving gefitinib and other receptor tyrosine kinase inhibitors.

Main Methods:

• Analysis of cancer cell lines exhibiting gefitinib resistance.
• Investigating the role of type II receptor tyrosine kinases (RTKs), specifically IGF-IR and InsR.
• Evaluating the efficacy of combination therapies targeting EGFR and IGF-IR/InsR.

Main Results:

• Insulin-like growth factor-I receptor (IGF-IR) and/or insulin receptor (InsR) mediate gefitinib resistance in various cancer types.
• Targeting IGF-IR/InsR is crucial for overcoming both de novo and acquired resistance phenotypes.
• Combination strategies targeting both EGFR and IGF-IR/InsR significantly enhance anti-tumour effects.

Conclusions:

• The IGF-IR and InsR are key players in gefitinib resistance.
• Combined inhibition of EGFR and IGF-IR/InsR represents a promising therapeutic strategy.
• This approach can improve treatment outcomes for patients with gefitinib-resistant cancers.